Literature DB >> 12876094

Neurologic manifestations and outcome of West Nile virus infection.

James J Sejvar1, Maryam B Haddad, Bruce C Tierney, Grant L Campbell, Anthony A Marfin, Jay A Van Gerpen, Aaron Fleischauer, A Arturo Leis, Dobrivoje S Stokic, Lyle R Petersen.   

Abstract

CONTEXT: The neurologic manifestations, laboratory findings, and outcome of patients with West Nile virus (WNV) infection have not been prospectively characterized.
OBJECTIVE: To describe prospectively the clinical and laboratory features and long-term outcome of patients with neurologic manifestations of WNV infection. DESIGN, SETTING, AND PARTICIPANTS: From August 1 to September 2, 2002, a community-based, prospective case series was conducted in St Tammany Parish, La. Standardized clinical data were collected on patients with suspected WNV infection. Confirmed WNV-seropositive patients were reassessed at 8 months. MAIN OUTCOME MEASURES: Clinical, neurologic, and laboratory features at initial presentation, and long-term neurologic outcome.
RESULTS: Sixteen (37%) of 39 suspected cases had antibodies against WNV; 5 had meningitis, 8 had encephalitis, and 3 had poliomyelitis-like acute flaccid paralysis. Movement disorders, including tremor (15 [94%]), myoclonus (5 [31%]), and parkinsonism (11 [69%]), were common among WNV-seropositive patients. One patient died. At 8-month follow-up, fatigue, headache, and myalgias were persistent symptoms; gait and movement disorders persisted in 6 patients. Patients with WNV meningitis or encephalitis had favorable outcomes, although patients with acute flaccid paralysis did not recover limb strength.
CONCLUSIONS: Movement disorders, including tremor, myoclonus, and parkinsonism, may be present during acute illness with WNV infection. Some patients with WNV infection and meningitis or encephalitis ultimately may have good long-term outcome, although an irreversible poliomyelitis-like syndrome may result.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12876094     DOI: 10.1001/jama.290.4.511

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  179 in total

Review 1.  West Nile virus: a growing concern?

Authors:  L Hannah Gould; Erol Fikrig
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  A short N-terminal peptide motif on flavivirus nonstructural protein NS1 modulates cellular targeting and immune recognition.

Authors:  Soonjeon Youn; Hyelim Cho; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

3.  West Nile virus infection induces depletion of IFNAR1 protein levels.

Authors:  Jared D Evans; Rachel A Crown; Ji A Sohn; Christoph Seeger
Journal:  Viral Immunol       Date:  2011-08       Impact factor: 2.257

4.  Alpha-Synuclein Expression Restricts RNA Viral Infections in the Brain.

Authors:  Erica L Beatman; Aaron Massey; Katherine D Shives; Kristina S Burrack; Mastooreh Chamanian; Thomas E Morrison; J David Beckham
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

Review 5.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

Review 6.  West Nile Virus: biology, transmission, and human infection.

Authors:  Tonya M Colpitts; Michael J Conway; Ruth R Montgomery; Erol Fikrig
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 7.  West Nile virus infection and immunity.

Authors:  Mehul S Suthar; Michael S Diamond; Michael Gale
Journal:  Nat Rev Microbiol       Date:  2013-02       Impact factor: 60.633

8.  Differential induction of type I interferon responses in myeloid dendritic cells by mosquito and mammalian-cell-derived alphaviruses.

Authors:  Reed S Shabman; Thomas E Morrison; Christopher Moore; Laura White; Mehul S Suthar; Linda Hueston; Nestor Rulli; Brett Lidbury; Jenny P-Y Ting; Suresh Mahalingam; Mark T Heise
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Novel strategy for treatment of viral central nervous system infection by using a cell-permeating inhibitor of c-Jun N-terminal kinase.

Authors:  J David Beckham; Robin J Goody; Penny Clarke; Christophe Bonny; Kenneth L Tyler
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

Review 10.  Diagnostic Approach for Arboviral Infections in the United States.

Authors:  Anne Piantadosi; Sanjat Kanjilal
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.